Evidence map›Paper›PMID 37462979›Full record

ArticleChemistry (Weinheim an der Bergstrasse, Germany)2023

Heterocyclic Merging of Stereochemically Diverse Chiral Piperazines and Morpholines with Indazoles.

Amol B Viveki, Timothy M Mansfield, Kevin A Tran, Evan Lenkeit, Kevin R MacKenzie, Damian W Young, Srinivas Chamakuri

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Amol B VivekiVerna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.
Timothy M MansfieldDepartment of Chemistry, Rice University, 6100 Main Street, Houston, TX 77005, USA.
Kevin A TranCenter for Drug Discovery, Department of Pathology and Immunology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.
Evan LenkeitDepartment of Chemistry, Rice University, 6100 Main Street, Houston, TX 77005, USA.
Kevin R MacKenzieCenter for Drug Discovery, Department of Pathology and Immunology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.
Damian W YoungCenter for Drug Discovery, Department of Pathology and Immunology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.
Srinivas ChamakuriCenter for Drug Discovery, Department of Pathology and Immunology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.ORCID https://orcid.org/0000-0002-7586-4992

Funding

Neutron encoded activity based probesR01GM139295 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI YOUNG, DAMIAN WINSTON, YOUNG, NICOLAS L · 2020 to 2024
$2.2M
Bill & Melinda Gates Foundation INV-001902NIGMS NIH HHS R01 GM139295NIGMS NIH HHS R01GM139295
6 · The paper itself

Abstract

We report a heterocyclic merging approach to construct novel indazolo-piperazines and indazolo-morpholines. Starting from chiral diamines and amino alcohols, novel regiochemically (1,3 and 1,4) and stereochemically diverse (relative and absolute) cohorts of indazolo-piperazines and indazolo-morpholines were obtained within six or seven steps. The key transformations involved are a Smiles rearrangement to generate the indazole core structure and a late-stage Michael addition to build the piperazine and morpholine heterocycles. We further explored additional vector diversity by incorporating substitutions on the indazole aromatic ring, generating a total of 20 unique, enantiomerically pure heterocyclic scaffolds.

Indexed as

chiral morpholineschiral piperazinesfused heterocyclesindazolesscaffold merging

Identifiers

PMID37462979
PMCPMC10885319

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.